ScoreWhy is C4 Therapeutics, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 2.64% and Operating profit at -196.31% over the last 5 years
2
Flat results in Jun 25
- NET SALES(Q) At USD 6.46 MM has Fallen at -35.02%
- ROCE(HY) Lowest at -52.99%
- RAW MATERIAL COST(Y) Grown by 18.57% (YoY)
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -43.38%, its profits have risen by 16.1%
4
Below par performance in long term as well as near term
- Along with generating -43.38% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is C4 Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
C4 Therapeutics, Inc.
-36.21%
-0.48
101.03%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
2.64%
EBIT Growth (5y)
-196.31%
EBIT to Interest (avg)
-76.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.12
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.63
EV to EBIT
0.74
EV to EBITDA
0.79
EV to Capital Employed
6.15
EV to Sales
-2.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
830.90%
ROE (Latest)
-52.92%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET PROFIT(HY)
Higher at USD -52.34 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -87.11 %
-6What is not working for the Company
NET SALES(Q)
At USD 6.46 MM has Fallen at -35.02%
ROCE(HY)
Lowest at -52.99%
RAW MATERIAL COST(Y)
Grown by 18.57% (YoY
Here's what is working for C4 Therapeutics, Inc.
Net Profit
Higher at USD -52.34 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -87.11 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Depreciation
Highest at USD 2.08 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for C4 Therapeutics, Inc.
Net Sales
At USD 6.46 MM has Fallen at -35.02%
over average net sales of the previous four periods of USD 9.95 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Raw Material Cost
Grown by 18.57% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
